OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	7691.0019	0/2	Appin. No.	09/836,477		RECEIVED	
Applicant	LARDER et al. 3 My				JUN 1 7 2002		
Filing Date	April 18, 2001	1700 S	Group:	3736	Te	echnology Center 2	
	The state of the s	4					
·	<u> </u>	MARKUSE PATEN	T DOCUMENTS	· · · · · · · · · · · · · · · · · · ·			
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate	
						₽	
					<u>*</u>	4 10	
		FOREIGN PATI	ENT DOCUMEN	TS	R. TAOLO	No to	
	Document Number	Publication Date	Country	Class	Sub Class	Translation Xes of No	
					•	B	
,						8	
····	OTHER DOCUMEN	TS (Including Au	thor, Title, Date	, Pertinent P	ages, Etc.)		
LAC	Harrigan et al., "Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting", AIDS, 13, pp. 1863-1871, (1999)						
140	Hertogs et al., "Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis", AIDS, 13(14), Poster Abstracts OP3.4, p. 11						

LAC	Harrigan et al., "Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting", AIDS, 13, pp. 1863-1871, (1999)
LAC	Hertogs et al., "Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis", AIDS, 13(14), Poster Abstracts OP3.4, p. 11
LHC	Vandamme et al., "Managing Resistance to Anti-HIV Drugs —An important Consideration for Effective Disease Management", DRUGS 1999, 57(3), pp. 337-361, (1999)
LAC	Walter et al., "Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors", Journal of Clinical Virology, 13, pp. 71-80, (1999)
LAC	Wegner et al., "Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel", AIDS, 14, pp. 1009-1015, (2000)

Examiner	Louistilling	Date Considered 7/2/04				
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce				